Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise
A trial is underway to assess the combination of adagrasib, pembrolizumab, and chemotherapy in KRAS G12C mutated NSCLC.
Asset / Drug
Drug and asset intelligence for Adagrasib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.